Wedbush analyst Andreas Argyrides downgraded Unity Biotechnology to Neutral from Outperform with a price target of $2, down from $3.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on UBX:
Wedbush analyst Andreas Argyrides downgraded Unity Biotechnology to Neutral from Outperform with a price target of $2, down from $3.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on UBX: